Trial Profile

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palupiprant (Primary) ; Durvalumab
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

16 Apr 2025 Status changed from not yet recruiting to withdrawn prior to enrolment as research was cancelled
12 Dec 2023 Planned initiation date changed from 30 Oct 2023 to 30 Jan 2024.
17 Sep 2023 Planned initiation date changed from 30 May 2023 to 30 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com